JPH0228109A - Preventive and treating agent for disease caused by immunological dysfunction - Google Patents
Preventive and treating agent for disease caused by immunological dysfunctionInfo
- Publication number
- JPH0228109A JPH0228109A JP14887989A JP14887989A JPH0228109A JP H0228109 A JPH0228109 A JP H0228109A JP 14887989 A JP14887989 A JP 14887989A JP 14887989 A JP14887989 A JP 14887989A JP H0228109 A JPH0228109 A JP H0228109A
- Authority
- JP
- Japan
- Prior art keywords
- humans
- animals
- preventive
- pneumonia
- treating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003449 preventive effect Effects 0.000 title claims abstract description 7
- 201000010099 disease Diseases 0.000 title claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 13
- 230000004064 dysfunction Effects 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 13
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960000735 docosanol Drugs 0.000 claims abstract description 5
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 14
- 208000026278 immune system disease Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 19
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 206010035664 Pneumonia Diseases 0.000 abstract description 8
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 201000011510 cancer Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 206010012735 Diarrhoea Diseases 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 3
- 241000283690 Bos taurus Species 0.000 abstract description 2
- 208000006758 Marek Disease Diseases 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 208000004396 mastitis Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000271566 Aves Species 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 8
- 244000144972 livestock Species 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- -1 etc. as necessary Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、ヒトまたは動物の免疫機能不全による疾患の
予防・治療剤、特にヒトまたは動物の感染症に対する防
禦剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a prophylactic/therapeutic agent for diseases caused by immune dysfunction in humans or animals, and particularly to an agent for preventing infectious diseases in humans or animals.
更に詳しく述べれば、ドコサノールを有効成分とするヒ
トまたは動物の免疫機能不全による疾患の予防・治療剤
、特にヒトまたは動物の感染症に対する防禦剤に関する
。More specifically, the present invention relates to a prophylactic/therapeutic agent for diseases caused by immune dysfunction in humans or animals, which contains docosanol as an active ingredient, and particularly to an agent for preventing infectious diseases in humans or animals.
近年、免疫学の進歩が急速であり、種々の疾患が免疫機
能不全に起因しているものと考えられてきている。例え
ば、癌、細菌感染症、喘息、関節リウマチ、自己免疫疾
患などが免疫機能不全に起因している疾患としてあげら
れている。In recent years, advances in immunology have been rapid, and various diseases are thought to be caused by immune dysfunction. For example, cancer, bacterial infections, asthma, rheumatoid arthritis, autoimmune diseases, and the like are listed as diseases caused by immune dysfunction.
細菌感染症は、単に病原菌の侵入のみによる単純性感染
症に加えて、各種重篤な基礎疾患を伴う複雑性感染症の
増加が深刻な問題となってきている。例えば癌に伴う感
染症は臨床上膜もわずられしい問題である。癌を担うこ
とによって、全身性、局所的な抵抗力低下を招き、易感
染状態下で感染症を合併、続発する。癌に伴う感染は、
初期においては呼吸器感染、尿路感染、胎道感染、皮膚
感染が多く、末期においては肺炎、敗血症が多い。この
腫瘍に伴う感染症併発の機序については、次のような過
程が一般的である。BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND Bacterial infections are becoming a serious problem, with an increase in complex infections accompanied by various serious underlying diseases, in addition to simple infections caused solely by the invasion of pathogenic bacteria. For example, infectious diseases associated with cancer are clinically problematic. Carrying cancer leads to a systemic and local decrease in resistance, leading to complications and subsequent infections in immunocompromised conditions. Infections associated with cancer are
In the early stages, respiratory tract infections, urinary tract infections, fetal canal infections, and skin infections are common, and in the final stages, pneumonia and sepsis are common. The following process is the general mechanism of infection associated with this tumor.
すなわち、白血病、唱性リンパ腫、癌の進展に伴い、正
常な組織、細胞の障害、特にリンパ系細胞や、顆粒球細
胞機能の低下をきたすので、易感染性となり、感染症を
併発すると考えられている。このような場合、抗生剤投
与による根治効果が乏しく、反復感染、菌交代症、難治
感染にいたることが多い。したがって、従来の抗生剤、
化学療法剤のみでは根治がほとんど期待できず、生体防
禦機能の改善なくしては治療不可能であり、生体の防御
機能を高める薬剤の開発が望まれている。In other words, as leukemia, lymphoma, and cancer progress, they cause damage to normal tissues and cells, especially lymphoid cells and granulocyte cell function, which makes them susceptible to infection and is thought to cause complications. ing. In such cases, antibiotic administration has little curative effect, often leading to repeated infections, bacterial replacement, and intractable infections. Therefore, conventional antibiotics,
Chemotherapeutic agents alone cannot be expected to provide a complete cure, and treatment is not possible without improving the body's defense function, so the development of drugs that enhance the body's defense function is desired.
一方、家畜・家禽などの動物の細菌感染に対しては、抗
生物質がその中心的存在となっており、事実、各種の抗
生物質の登場によって病原細菌による重篤な感染症は減
少している。しかし、畜産界では抗菌剤の乱用から、畜
水産物中の残留・耐性菌の増加、菌交代症などを引き起
こし、社会問題となっている。すなわち、宿主は感染防
禦能が著しく低下し、感染症に対する修復機能も障害さ
れているため、細菌感染症は治りにくく、再感染し易い
状態を作っている。On the other hand, antibiotics play a central role in combating bacterial infections in animals such as livestock and poultry, and in fact, serious infections caused by pathogenic bacteria are decreasing with the introduction of various antibiotics. . However, in the livestock industry, overuse of antibacterial agents has caused a rise in residual and resistant bacteria in livestock and marine products, and bacterial replacement disease, which has become a social problem. In other words, the host's ability to fight off infections is significantly reduced and its repair function against infections is impaired, making bacterial infections difficult to cure and creating a state where reinfection is easy.
更に、自発性感染症（日和見感染ｆＭ、）が家畜の生産
性を低下させ、その損失は大きい。そこで宿主の免疫能
の活性を高め、生体の防禦機能を高める必要がある。Furthermore, spontaneous infections (opportunistic infections, fM,) reduce livestock productivity, resulting in large losses. Therefore, it is necessary to increase the activity of the host's immune system and enhance the defense function of the living body.
本発明者等は、上述の実情に鑑み、免疫機能を正常化し
、生体の防禦機能を高める薬剤について長年鋭意研究し
てきたが、意外にもドコサノールがヒトおよび動物の免
疫機能不全による疾患の予防・治療剤、特にヒトおよび
動物の感染症に対する防禦剤として有効であることを見
出し、本発明を完成したものである。In view of the above-mentioned circumstances, the present inventors have been conducting intensive research for many years on drugs that normalize the immune function and enhance the defense function of the living body, but surprisingly, docosanol has been found to be effective in preventing diseases caused by immune dysfunction in humans and animals. The present invention was completed based on the discovery that the present invention is effective as a therapeutic agent, particularly as a preventive agent against infectious diseases in humans and animals.
すなわち、本発明化合物は、ヒトおよび動物の免疫機能
を正常化し、感染抵抗性を高める作用を有するので、ヒ
トおよび動物の免疫機能不全による疾患の予防・治療剤
、各種感染症に対する防禦剤として有用である。That is, the compound of the present invention has the effect of normalizing the immune function of humans and animals and increasing resistance to infection, and is therefore useful as a prophylactic/therapeutic agent for diseases caused by immune dysfunction in humans and animals, and as a preventive agent against various infectious diseases. It is.
ヒトの場合の具体例をあげれば、関節リウマチ、自己免
疫疾患、癌、喘息、および例えば敗血症、肺炎、髄膜炎
、各種ウィルス感染症などの各種感染症などに有効であ
る。To give specific examples in humans, it is effective against rheumatoid arthritis, autoimmune diseases, cancer, asthma, and various infectious diseases such as sepsis, pneumonia, meningitis, and various viral infections.
また動物の場合の具体例をあげれば、例えば豚の下痢、
肺炎（ＳＥＰ、ＡＲ，ヘモフィルス、パスツレラ） 、
ＴＧＥ、８の肺炎（マイクロプラズマ、ヘモフィルス）
、マレック病、牛の下痢、肺炎、乳房炎などにを効であ
る。In addition, specific examples of animals include diarrhea in pigs,
Pneumonia (SEP, AR, Haemophilus, Pasteurella),
TGE, 8 pneumonia (Microplasma, Haemophilus)
It is effective against Marek's disease, bovine diarrhea, pneumonia, mastitis, etc.
また、ヒｌよび動物の感染症に本発明化合物を投与する
場合、抗生物質との併用により著しくその治療効果を高
める。このことは、前述した畜産業界で問題となってい
る抗生物質の乱用という問題をも解決するものであり、
重要な意義がある。Furthermore, when the compounds of the present invention are administered to treat infectious diseases in leeches and animals, their therapeutic effects are significantly enhanced when used in combination with antibiotics. This also solves the problem of overuse of antibiotics, which is a problem in the livestock industry mentioned above.
It has important meaning.
更に、家畜・家禽などの動物の場合を例にとれば、生体
の感染抵抗性を高めるので、初生時のベース薬として有
用であること、多頭羽飼育、輸送などに起因するストレ
スの緩和に有用であること、およびワクチン効果の増強
に有用である。Furthermore, in the case of animals such as livestock and poultry, it increases the organism's resistance to infection, so it is useful as a base drug at the beginning of life, and it is useful for alleviating stress caused by raising multiple birds and transporting them. and is useful for enhancing vaccine efficacy.
したがって、本発明の目的は、ヒトおよび動物の免疫機
能不全の新規な予防・治療剤を提供するにある。Therefore, an object of the present invention is to provide a novel prophylactic/therapeutic agent for immune dysfunction in humans and animals.
更に、本発明の目的は、ヒトおよび動物の感染症に対す
る新規な防禦剤を提供するにある。A further object of the present invention is to provide a novel protective agent against infectious diseases in humans and animals.
験例
感染防禦効果
（］） 実験方法
ｓｌｃ：ＩＣＲ雄性マウス（６〜７週令、体重２２〜３
０ｇ）に、下記に記載した被験化合物を次表（表１）に
示す量筋肉内投与し、２４時間後に臨床由来の大腸菌（
ＥｓｃｈｅｒｉｃｈｉａＣｏｌｉ）を２．８Ｘ１０’／
マウスを皮下接種し、感染後７日目の生存数から生存率
を求めた。Experimental example infection prevention effect (]) Experimental method slc: ICR male mice (6-7 weeks old, body weight 22-3
The test compound described below was intramuscularly administered in the amount shown in the following table (Table 1) to a clinically derived E. coli (0g).
Escherichia coli) 2.8X10'/
Mice were subcutaneously inoculated, and the survival rate was determined from the number of survivors 7 days after infection.
（２）被験化合物
化合物、へニ
ドコサノール
対照化合物： ＭＤＰ（Ａｃ！、ｆｕｒ−Ｌ−Ａｌａ−
Ｄ−Ｇｌｕ）（３）実験結果
結果を表１に示す。(2) Test compound, henidocosanol control compound: MDP (Ac!, fur-L-Ala-
D-Glu) (3) Experimental results The results are shown in Table 1.
表
上記の実験例により、本発明化合物は免疫機能を正常化
し、感染抵抗性を高めることが明らかとなった。The experimental examples shown in the table above revealed that the compounds of the present invention normalize immune function and increase resistance to infection.
本発明化合物は、極めて毒性の低いものであり、安全性
は非常に高いものであり、したがって長期連用投与が可
能であり、この意味でも本発明の価値は高い。The compounds of the present invention have extremely low toxicity and are extremely safe, and therefore can be administered continuously over a long period of time, and in this sense, the value of the present invention is high.
すなわち、ＳＤ系ラット（体重２００ｇ） に前記の
化合物Ａを５００ｍｇ／ｋｇ経口投与したが、死亡例、
副作用は何ら観察されなかった。That is, when 500 mg/kg of the above compound A was orally administered to SD rats (body weight 200 g), there were no cases of death or death.
No side effects were observed.
本発明化合物をヒトの免疫機能不全による疾患の予防・
治療剤、あるいはヒトの感染症に対する防禦剤として思
考に投与する際の投与量は、疾患の種類、症状の程度な
どにより大きく異なり、特に限定さねないが、成人１日
あたり約１０ｍｇ〜４，０００ｍｇ 、好ましくは５０
ｍｇ〜５００ｍｇを経口若しくは非経口的に投与する。The compounds of the present invention can be used to prevent and treat diseases caused by immune dysfunction in humans.
The dosage when administered as a therapeutic agent or preventive agent against human infectious diseases varies greatly depending on the type of disease, severity of symptoms, etc., and is not particularly limited, but it is approximately 10 mg to 4,000 mg per day for adults. 000mg, preferably 50
mg to 500 mg orally or parenterally.
感染症に対する防禦剤として投与する場合、抗生物質と
の併用はもちろん差し支えない。投与剤型としては、例
えば散剤、細粒剤、顆粒剤、錠剤、カプセル剤、注射剤
などがあげられる。製剤化の際は、通常の製剤担体を用
い、常法により製造する。When administered as a preventative against infectious diseases, it may of course be used in combination with antibiotics. Examples of dosage forms include powders, fine granules, granules, tablets, capsules, and injections. When preparing a formulation, it is produced by a conventional method using a conventional pharmaceutical carrier.
すなわち、経口用固形製剤を調製する場合は、生薬に賦
形剤、更に必要に応じて結合剤、崩壊剤、滑沢剤、着色
剤、矯味矯臭剤などを加えた後、常法により錠剤、被覆
錠剤、顆粒剤、散剤、カプセル剤などとする。That is, when preparing a solid preparation for oral use, after adding excipients to the crude drug, and further adding binders, disintegrants, lubricants, coloring agents, flavoring agents, etc. as necessary, tablets, Form into coated tablets, granules, powders, capsules, etc.
賦形薬としては、例えば乳糖、コーンスターチ、白糖、
ブドウ糖、ソルビット、結晶セルロースなどが、結合剤
としては、例えばポリビニルアルコール、ポリビニルエ
ーテノベエチルセルロース、メチルセルロース、アラビ
アゴム、トラガント、ゼラチン、シェラツク、ヒドロキ
シプロピルセルロース、ヒドロキシプロピルスターチ、
ポリビニルピロリドンなどが、崩壊剤としては、例えば
デンプン、寒天、ゼラチン末、結晶セルロース、炭酸カ
ルシウム、炭酸水素ナトリウム、クエン酸カルシウム、
デキストリン、ペクチン等が、滑沢剤としては、例えば
ステアリン酸マグネシウム、タルク、ポリエチレングリ
コーノペシリ力、硬化植物油等が、着色剤としては医薬
品に添加することが許可されているものが、矯味矯臭剤
としては、ココア末、ハツカ脳、芳香酸、ハツカ油、電
脳、桂皮末等が用いろれる。これらの錠剤、顆粒剤には
糖衣、ゼラチン衣、その他必要により適宜コーティング
することはもちろん差し支えない。Examples of excipients include lactose, cornstarch, white sugar,
Glucose, sorbitol, crystalline cellulose, etc., and binders include, for example, polyvinyl alcohol, polyvinylethenobeethyl cellulose, methyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropyl starch,
Polyvinylpyrrolidone, etc., and examples of disintegrants include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium hydrogen carbonate, calcium citrate,
Dextrin, pectin, etc. are used as lubricants, such as magnesium stearate, talc, polyethylene glycol, hydrogenated vegetable oil, etc., and colorants that are permitted to be added to pharmaceuticals are used as flavoring agents. As the agent, cocoa powder, peppermint, aromatic acid, peppermint oil, cybernetic root, cinnamon powder, etc. can be used. Of course, these tablets and granules may be coated with sugar coating, gelatin coating, or other coatings as appropriate.
注射剤を調製する場合には、主剤に必要によりｐＨ調整
剤、緩衝剤、安定化剤、保存剤、可溶化剤などを添加し
、常法により皮下、筋肉内、静脈内用注射剤とする。When preparing injections, add pH adjusters, buffers, stabilizers, preservatives, solubilizers, etc. to the base agent as necessary, and prepare subcutaneous, intramuscular, or intravenous injections using conventional methods. .
家畜、家乳などの動物に投与する際も、経口投与若しく
は非経口投与により投与する。経口投与は通常飼料に添
加して行う。また非経口投与の例をあげれば、常法によ
り注射剤を調製し、皮下、筋肉内、静脈内などに投与す
る。When administering to animals such as livestock and domestic milk, the drug is administered orally or parenterally. Oral administration is usually done by adding it to feed. As an example of parenteral administration, an injection is prepared by a conventional method and administered subcutaneously, intramuscularly, intravenously, etc.
Claims (1)
疫機能不全による疾患の予防・治療剤。 ２ ヒトまたは動物の免疫機能不全による疾患の予防・
治療が、ヒトまたは動物の感染症に対する防禦である特
許請求の範囲第１項記載のヒトまたは動物の免疫機能不
全による疾患の予防・治療剤。[Scope of Claims] 1. A prophylactic/therapeutic agent for diseases caused by immune dysfunction in humans or animals, containing docosanol as an active ingredient. 2. Prevention of diseases caused by immune dysfunction in humans or animals.
The preventive/therapeutic agent for diseases caused by immune dysfunction in humans or animals according to claim 1, wherein the treatment is protection against infectious diseases in humans or animals.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14887989A JPH0228109A (en) | 1989-06-12 | 1989-06-12 | Preventive and treating agent for disease caused by immunological dysfunction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14887989A JPH0228109A (en) | 1989-06-12 | 1989-06-12 | Preventive and treating agent for disease caused by immunological dysfunction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18364282A Division JPS5973513A (en) | 1982-05-28 | 1982-10-21 | Preventive and remedy for disease caused by immunological function insufficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0228109A true JPH0228109A (en) | 1990-01-30 |
| JPH0325405B2 JPH0325405B2 (en) | 1991-04-05 |
Family
ID=15462763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14887989A Granted JPH0228109A (en) | 1989-06-12 | 1989-06-12 | Preventive and treating agent for disease caused by immunological dysfunction |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0228109A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0527023A (en) * | 1991-07-19 | 1993-02-05 | Nec Corp | Secondary radar target tracking device |
-
1989
- 1989-06-12 JP JP14887989A patent/JPH0228109A/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0527023A (en) * | 1991-07-19 | 1993-02-05 | Nec Corp | Secondary radar target tracking device |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0325405B2 (en) | 1991-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110151594B (en) | Oral composition containing ectoin and hyaluronic acid and application thereof | |
| US6461646B2 (en) | Pharmaceutical composition for preventing and/or curing digestive disorders | |
| KR100919725B1 (en) | Composition for treatment and prophylaxis of diseases and infections of poultry | |
| US5945420A (en) | Immunopotentiating and infection protective agent and production thereof | |
| SE502924C2 (en) | Pharmaceutical composition containing an effective amount of 3,7,11,15-tetramethyl-hexadeca-1-en-3-ol or 3,7,11,15-tetramethyl-1,6,10,14-hexadecatetraen-3-ol | |
| JP2001503430A (en) | Methods for treating animals that enhance natural killer lymphocyte function | |
| WO2001019375A1 (en) | Inhibiting t-cell proliferation | |
| JP4394686B2 (en) | Pharmaceutical composition for promoting salivation and use thereof | |
| JPH0228109A (en) | Preventive and treating agent for disease caused by immunological dysfunction | |
| JP3636207B2 (en) | Immunostimulatory / infection-preventing agent and method for producing the same | |
| CA2353805A1 (en) | Use of phytanic acid for the treatment of diabetes | |
| EP1663225B1 (en) | Compositions for veterinary and medical applications | |
| JPS5973513A (en) | Preventive and remedy for disease caused by immunological function insufficiency | |
| JP2599163B2 (en) | Prevention and treatment of Salmonella tefimurium infection in livestock and poultry | |
| US3836650A (en) | Method for combating marek's disease in poultry | |
| JPS58225014A (en) | Preventive and remedy for disease caused by incompetence of immune function | |
| AU2004267873C1 (en) | Compositions for veterinary and medical applications | |
| WO1986000225A1 (en) | Inhibition of tumor development | |
| WO2022158885A1 (en) | Composition comprising coffee, coffee extract, and byproduct as active ingredient for prevention of cancer metastasis or for alleviation or treatment of cancer | |
| JPH026326B2 (en) | ||
| JPWO2007074727A1 (en) | Oral candidiasis treatment | |
| JPS59144718A (en) | Antibacterial agent | |
| US3767804A (en) | Method of combatting malaria | |
| KR20010108040A (en) | Anti-hiv infection agents and method for treating hiv infection | |
| KR20050068196A (en) | Pharmatheutical composition for anti-cancer and anti-cancer adjuvent |